Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity.

PURPOSE To evaluate the early side effects of a short course hypofractionated radiotherapy regimen in prostate cancer. MATERIALS AND METHODS Three institutions (IRE, AZ VUB, GUH) included 36 patients with T1-T3N0M0 prostate cancer in a phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Early side effects were scored using the RTOG/EORTC criteria and the international prostate symptom index (IPSI) weekly during treatment and 1 and 2 months afterwards. The results were compared with two control groups of patients previously treated with conventional fractionation at AZ VUB (238 patients) and GUH (114 patients). RESULTS None of the patients experienced grade 3-4 toxicity. Grade 1-2 Gastro-intestinal (GI), grade 2 GI, grade 1-2 Genito-urinary (GU) and grade 2 GU toxicity occurred in 75%, 36%, 75% and 44% for the hypofractionation schedule. The corresponding figures were 25-44%, 6-29%, 47-53% and 16-44% for the control groups (p<0.01 for grade 1-2 GI and GU toxicity). Two months after treatment all GU and the majority of GI symptoms had resolved. The IPSI increased from (average +/-1 SD) 5.6+/-4 pre-treatment to 10.0+/-6 during week 2-4 and had normalized (5.2+/-4) two months after treatment. CONCLUSIONS Though no grade 3-4 side effects were observed, the investigated schedule results in a marked increase of grade 1-2 early side effects as compared to a conventional regimen. Side effects resolved within two months post-treatment.

[1]  E. Hall,et al.  Radiobiology for the radiologist , 1973 .

[2]  R. Fraser,et al.  Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. , 2003, International journal of radiation oncology, biology, physics.

[3]  X. Allen Li,et al.  HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .

[4]  V. Khoo,et al.  Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. , 2002, International journal of radiation oncology, biology, physics.

[5]  H. Bartelink,et al.  Fractionation in radiotherapy. , 1994, Cancer treatment reviews.

[6]  Roberto Orecchia,et al.  Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Michael J. Zelefsky,et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.

[8]  J. Fowler,et al.  New data on the value of α/β—evidence mounts that it is low , 2004 .

[9]  W. Tomé,et al.  A Multi-Institutional Phase I/II Trial of Dose-per-fraction Escalation for Localized Prostate Cancer , 2005 .

[10]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[11]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[12]  H. Kal,et al.  HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .

[13]  G H Fletcher,et al.  Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. , 1982, International journal of radiation oncology, biology, physics.

[14]  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2005 .

[15]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[16]  D J Brenner,et al.  Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.

[17]  W. De Neve,et al.  Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. , 2004, International journal of radiation oncology, biology, physics.

[18]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[19]  R. Pötter,et al.  Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Rick Chappell,et al.  Is α/β for prostate tumors really low? , 2001 .

[21]  B Pickett,et al.  Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.

[22]  A Pollack,et al.  Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. , 2000, International journal of radiation oncology, biology, physics.

[23]  E. B. Butler,et al.  Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. , 2001, International journal of radiation oncology, biology, physics.

[24]  D. Brenner,et al.  In response to Drs. King and Mayo: low α/β values for prostate appear to be independent of modeling details1 , 2000 .

[25]  P. Rust,et al.  Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  Patrick A Kupelian,et al.  Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. , 2005, International journal of radiation oncology, biology, physics.

[27]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[28]  Dirk Verellen,et al.  Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[29]  P. Lattuada,et al.  Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  F. Bartholomeusz,et al.  Anorectal Dysfunction Increases with Time Following Radiation Therapy for Carcinoma of the Prostate , 2004, American Journal of Gastroenterology.

[31]  A. Swan,et al.  Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). , 1990, Urology.

[32]  A. Nahum,et al.  Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the α/β ratio , 2003 .

[33]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[34]  G Starkschall,et al.  Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. , 1996, International journal of radiation oncology, biology, physics.

[35]  Filip Claus,et al.  Interobserver Delineation Variation Using CT versus Combined CT + MRI in Intensity–Modulated Radiotherapy for Prostate Cancer , 2005, Strahlentherapie und Onkologie.

[36]  P. Koper,et al.  Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. , 2005, International journal of radiation oncology, biology, physics.

[37]  D. Brenner,et al.  Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .

[38]  Franca Foppiano,et al.  Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  M. Roach,et al.  Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.